SurModics Showcases New Assay Application at Luminex xMAP Symposium

May 10, 2010 at 4:01 PM EDT

EDEN PRAIRIE, Minn., May 10, 2010 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that it is presenting a scientific poster on the use of its StabilGuard(R) Immunoassay Stabilizer (BSA-Free) product as a blocker in Luminex Corporation assays.

On behalf of SurModics, Mr. Tim Jentz will be presenting a poster titled: Novel Formulation for Eliminating Non-Specific Binding to Microspheres in Multiplexed Luminex Assays and Other IVD Applications on May 12th at 11:45 a.m. The poster illustrates the following benefits of SurModics' StabilGuard(R) Immunoassay Stabilizer product:

  • Reduces the non-specific binding of sera to microspheres in multiplex Luminex assays
  • Eliminates sera reactivity to BSA when substituted during the microsphere wash steps
  • Improves lot-to-lot consistency and sensitivity of the microspheres
  • Decreases microsphere concentration required for assays
  • Provides superior dried antibody stability
  • Provides strong blocking, decreased backgrounds, and enhanced detection limits with membrane based immunoassays
  • Demonstrates improved assay performance in multiple applications across the immunoassay diagnostic industry

"This poster highlights additional benefits of the StabilGuard(R) Immunoassay Stabilizer/Blocker products and the flexibility of our in vitro diagnostic technology," said Bruce Barclay, President and CEO of SurModics. "SurModics is committed to developing additional products based on this technology, so our customers can better address the needs of their patients."

To learn more about SurModics' in vitro diagnostics products, please visit with Mr. Jentz following the presentation, visit our website (, or contact customer service at 952-829-2709 or

About SurModics, Inc.

SurModics' vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, such as those regarding the ability of our partners to commercialize products using our technologies, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including those identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2009, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at and at the SEC website at Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

SOURCE: SurModics, Inc.

SurModics, Inc.
Phil Ankeny, Senior Vice President and Chief Financial Officer
(952) 829-2700